Ишемический инсульт как первое проявление антрациклиновой кардиомиопатии

Данная статья посвящена обсуждению кардиоэмболических осложнений антрациклиновой кардиомиопатии. В статье описан клинический случай кардиотоксичности, вызванной агрессивной неоадъювантной химиотерапией у пациентки с раком молочной железы и осложнившейся развитием кардиоэмболического ишемического инсульта.

1. Шамалов Н.А., Кустова М.А. Криптогенный инсульт. Неврология, нейропсихиатрия, психосоматика. 2014;(спецвыпуск 2):42-49.

2. Bang O, Lee P, Joo S, Lee J, Joo I, Huh K. Frequency and mechanisms of stroke recurrence after cryptogenic stroke. Ann Neurol. 2003;54(2):227-234. https://doi.org/10.1002/ana.10644

3. Gon Y, Okazaki S, Terasaki Y et al. Characteristics of cryptogenic stroke in cancer patients. Ann Clin Transl Neurol. 2016;3(4):280-287. https://doi.org/10.1002/acn3.291

4. Graus F, Rogers L, Posner J. Cerebrovascular Complications in Patients with Cancer. Medicine (Baltimore). 1985;64(1):16-35. https://doi.org/10.1097/00005792-198501000-00002

5. Chen P, Muo C, Lee Y, Yu Y, Sung F. Lung Cancer and Incidence of Stroke. Stroke. 2011;42(11):3034-3039. https://doi.org/10.1161/strokeaha.111.615534

6. Bang O, Chung J, Lee M, Seo W, Kim G, Ahn M. Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. J Stroke. 2020;22(1):1-10. https://doi.org/10.5853/jos.2019.02278.

7. Iguchi Y, Kimura K, Kobayashi K, Ueno Y, Inoue T. Ischaemic stroke with malignancy may often be caused by paradoxical embolism. Journal of Neurology, Neurosurgery & Psychiatry. 2006;77(12):1336-1339. https://doi.org/10.1136/jnnp.2006.092940

8. Khorana A, Dalal M, Lin J, Connolly G. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2012;119(3):648-655. https://doi.org/10.1002/cncr.27772

9. Thompson C, Rodgers L. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci. 1952;223(5):469-478. https://doi.org/10.1097/00000441-195205000-00001

10. Volkova M, Russell R. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Curr Cardiol Rev. 2012;7(4):214-220. https://doi.org/10.2174/157340311799960645

11. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. The Lancet. 1992;339(8784). https://doi.org/10.1016/0140-6736(92)90139-t

12. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374-1403. https://doi.org/10.1016/j.ejca.2012.12.027

13. Siegel R, DeSantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241. https://doi.org/10.3322/caac.21149

14. Ewer M, Ewer S. Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology. 2015;12(9):547-558. https://doi.org/10.1038/nrcardio.2015.65

15. Гендлин Г.Е., Емелина Е.И., Никитин И.Г. и др. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. Российский кардиологический журнал. 2017;3(143):145–154.

16. Armstrong G, Oeffinger K, Chen Y et al. Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer. Journal of Clinical Oncology. 2013;31(29):3673-3680. https://doi.org/10.1200/jco.2013.49.3205

17. Richardson AJ, Leckie T, Watkins ER et al. Post marathon cardiac troponin T is associated with relative exercise intensity. J Sci Med Sport. 2018;21(9):880-884. https://doi.org/10.1016/j.jsams.2018.02.005

18. Curigliano G, Cardinale D, Suter T et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology. 2012;23:vii155-vii166. https://doi.org/10.1093/annonc/mds293

19. Swain S, Whaley F, Ewer M. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97(11):2869-2879. https://doi.org/10.1002/cncr.11407

20. Adams H, Bendixen B, Kappelle L et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41. https://doi.org/10.1161/01.str.24.1.35

21. Правдивцева Е.В., Потешкина Н.Г., Сванадзе А.М., и др. Профилактика кардиотоксического действия антрациклинового антибиотика доксорубицина: роль ингибитора ангиотензинпревращающего фермента периндоприла. Клиницист. 2011;5,3: 55-60.

22. Bosch X, Rovira M, Sitges M et al. Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies. J Am Coll Cardiol. 2013;61(23):2355-2362. https://doi.org/10.1016/j.jacc.2013.02.072

23. Kalay N, Basar E, Ozdogru I et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-2262. https://doi.org/10.1016/j.jacc.2006.07.052